louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00102856: Neuromodulation and Language Acquisition (Stage Ib)
Official title: Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib)
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Healthy
Keywords: language acquisition
plasticity
stroke recovery
associative learning
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
First posted: 2005-02-04
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.

Detailed description: Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a selective d2/d3 dopamine agonist (pramipexole) or cholinergic neuromodulation (rivastigmine), after a titration period of five days, will yield a learning enhancement comparable to using levodopa in healthy subjects. The expected scientific results will strengthen the basis for transferring neuromodulatory interventions from the laboratory to stroke patients with language dysfunctions.

Eligibility criteria: Inclusion Criteria:

* Healthy subjects
* 20-35 years old
* Right handedness
* Left language dominance (as assessed by functional transcranial Doppler ultrasonography \[fTCD\])

Exclusion Criteria:

* Neurological/psychiatric/metabolic/cardiac disorders
* Asthma
* Known allergic reactions to one of the experimental drugs
* Other drugs affecting the central nervous system
* Leisure drug ingestion during the past 4 weeks (urine test)
* Smoking cessation during the past 2 weeks
* \> 6 cups of coffee or energy drinks per day
* \> 10 cigarettes per day
* \> 50 grams of alcohol per day

Primary outcomes:
measure: Boost in language learning success (percent hits) through neuromodulation
Secondary outcomes:
measure: Stability of language learning success after one week, one month, and one year
Other outcomes:
Locations:
city: Muenster
country: Germany
facility: Dept. of Neurology, University Hospital Muenster
state: Nordrhein-Westfalen
Study officials:
affiliation: Dept. of Neurology, University Hospital Muenster
name: Caterina Breitenstein, PhD
role: STUDY_DIRECTOR
affiliation: Dept. of Neurology, University Hospital Muenster
name: Stefan Knecht, MD
role: STUDY_CHAIR
References:
citation: Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Floel A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6. doi: 10.1002/ana.20125.
citation: Breitenstein C, Wailke S, Bushuven S, Kamping S, Zwitserlood P, Ringelstein EB, Knecht S. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004 Sep;29(9):1704-14. doi: 10.1038/sj.npp.1300464.
Clinical trial NCT04654156: Assessment of Contrast Enhancement Boost for the Direct Identification of Pulmonary Emboli in Thoracic CT Angiography
Official title: Assessment of Contrast Enhancement Boost for the Direct Identification of Pulmonary Emboli in Thoracic CT Angiography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
Keywords: Pulmonary embolism
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-12-04
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient referred in our institution by emergency practitioners who underwent thoracic CT angiography for clinical suspicion of pulmonary embolism between March and June 2018

Brief summary: Pulmonary embolism is a common cardiovascular disease and thoracic CT angiography is currently considered the gold standard for its non-invasive diagnosis. However, the diagnostic performance of CT angiography can be hampered by an insufficient enhancement of pulmonary arteries. Contrast Enhancement Boost (CE Boost) is a post-processing technique using an iodine density map to artificially improve pulmonary artery enhancement.

This retrospective study compares standard CT-angiography images with CE Boost images to assess the potential improvement of diagnostic performance for the detection of pulmonary embolism.


Eligibility criteria: Inclusion Criteria:

* Patient who underwent thoracic CT angiography for suspicion of pulmonary embolism in our institution between March and June 2018

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of thrombi within each branch of the pulmonary arteries
timeFrame: Between March and June 2018
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHRU Nancy
state: Meurthe-et-Moselle
Study officials:
References:
Clinical trial NCT06602856: Point-of-care-ultrasound in Swiss Air Rescue Rega
Official title: The Benefits of Pre-hospital POCUS Examinations in Air Rescue
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Point-of-care-ultrasound
Emergency Treatment
Keywords: POCUS
Helicopter emergency medical service
Diagnostic quality
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The Swiss Air Rescue Rega treats more than 12,000 patients annually. It is estimated that 1,000 of these will undergo a prehospital POCUS examination. These include both trauma patients and patients with medical diseases such as pulmonary oedema, COPD, myocardial infarction, etc.

Brief summary: The aim of the study is, on the one hand, to objectively investigate the patient-oriented benefits of prehospital point-of-care ultrasound (POCUS) examinations under the conditions of the helicopter emergency medical services (HEMS) in Switzerland. On the other hand, the study will show what the diagnostic quality of prehospital POCUS examinations is and how emergency medical teams can be trained to use POCUS in the future.

HEMS crew members will answer a short online questionaire about how findings of their POCUS examination has influenced their medical treatment, diagnosis and selection of target hospital for the patient (primary outcome parameters).

In addition, a study nurse will query the findings of the in-hospital diagnostic tests and compare them with the findings of the pre-hospital POCUS examination. This will enable the investigators to evaluate the diagnostic quality of the prehospital POCUS examination and to identify which findings are often not recognised in the POCUS. The subjective satisfaction and assessment of the benefit of the POCUS examination by the respective users will also be recorded (secondary outcome parameters).


Eligibility criteria: Inclusion Criteria:

* All patients in whom the treating Rega team uses POCUS pre-hospital
* existing written General Consent (with permission to use patient data for research)

Exclusion Criteria:

* Age \&lt;18 years

Primary outcomes:
measure: Diagnosis
timeFrame: During HEMS mission, estimated to be on average of 30-60 minutes
measure: Therapeutic interventions
timeFrame: During HEMS mission, estimated to be on average 30-60 minutes
measure: Transportation target
timeFrame: During HEMS mission, estimated to be on average 30-60 minutes
Secondary outcomes:
measure: Missed findings
timeFrame: 1 day
measure: Users&#39; subjective assessment
timeFrame: 1 day
measure: Diagnostic quality
timeFrame: 1 day
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Swiss Air Rescue Rega
state: Zurich
Study officials:
affiliation: Bern University Hospital
name: Jürgen Knapp, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02666456: The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain
Official title: DOLORisk: Understanding Risk Factors and Determinants for Neuropathic Pain - The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neuropathic Pain
Polyneuropathy
Peripheral Nerve Injury
Lead sponsor: University of Kiel
Sponsor class: OTHER
First posted: 2016-01-28
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Painless patients and patients with chronic peripheral neuropathic pain.

Brief summary: Cross-sectional and longitudinal analysis of the somatosensory phenotype, assessed by quantitative sensory testing (QST) and Information obtained by questionnaires to detect risk factors for neuropathic pain development and chronification in painless and chronic pain patients.


Eligibility criteria: Inclusion Criteria:

* Chronic peripheral neuropathic pain or
* Painless Patient with risk to develop neuropathic pain (post-surgery, chemotherapy-induced)

Exclusion Criteria:

* Minors

Primary outcomes:
measure: Somatosensory phenotype detected by quantitative sensory testing (QST)
timeFrame: Single assessment at baseline (cross-sectional study). Report of complete cohort data at study completion
measure: Change of neuropathic pain: Development and chronification of neuropathic pain detected by DN4 questionnaire
timeFrame: Assessment of change of neuropathic pain from baseline and 6 months after study enrollment (longitudinal study). Report of complete cohort data at study completion.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01678456: Prospective Registration and Assessment of Serious Adverse Events Within the AFNET
Official title: Prospective Registration and Independent Assessment of Incidence, Clinical Relevance and Outcome of Serious Adverse Events (SAE) Registered in the German Competence Network on Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Assessment of Serious Advers Events
Thromboembolic and Bleeding Complications
Complications of Antiarrhythmic Drugs or Invasive Procedures
Assessment by a Critical Event Committee
Keywords: Atrial Fibrillation
Critical Event Committee
Serious adverse events
Thromboembolic complications
Cardiac and noncardiac complications
Bleeding complications
Acute heart failure
Syncope
Resuscitation
Lead sponsor: Atrial Fibrillation Network
Sponsor class: OTHER
First posted: 2012-09-05
Enrollment: 13000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Real-life population Patients with atrial fibrilation documented within the last 12 months before enrollment

Brief summary: Prospective registration and independent assessment of SAE associated with atrial fibrillation such as thromboembolic events, and other cardiac and noncardiac complications by a Critical Event Committee.

Detailed description: Atrial fibrillation (AF), the most common sustained rhythm disturbance, is associated with a significantly enhanced mortality and morbidity due to thromboembolic events, and other cardiac and noncardiac complications. Therefore the "Network of Competence on Atrial Fibrillation (AFNET)" supported by the German Ministry for Education and Research (BMBF) was established in order to collect clinical data on patients (pts) with AF (paroxysmal, persistent, permanent) over a study period of 6 years with an expected sample size of 12,000 pts. Incidence, clinical relevance and outcome after SAE is recorded and assessed by a Critical Event Committee (CEC).

The CEC-members (experts in cardiology and neurology) defined as SAE any death with or without relationship to AF, cardio-embolic events (stroke, peripheral arterial embolism), bleeding complications due to antithrombotic therapy, acute heart failure, syncope, resuscitation; additionally, the complication of interventional strategies for AF-treatment and other AF-independent SAEs.

Over a 3-year follow-up period, during 6-monthly and unscheduled visits, the SAEs are systematically documented, blinded and their relationship to AF will be interpreted in detail by the CEC.

Eligibility criteria: Inclusion Criteria:

* Atrial fibrillation documented by ECG not older then one year
* Age \> 18 years
* Informed consent

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Brandenburg
country: Germany
facility: Staedt. Klinikum, Department of Cardiology
Study officials:
affiliation: SAE-Zentrum Brandenburg/Havel Germany
name: Michael Oeff, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01366456: Clinical Trials for Comparison of Two Kinds of Moxibustion
Official title: Clinical Trials for Comparison Between Shingigu and Charcoal Moxa on CV-12
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Temperature Change
Keywords: Temperature Change
Moxibustion
Warming effect
Lead sponsor: Semyung University
Sponsor class: OTHER
Collaborators: name: Kyunghee University
First posted: 2011-06-06
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to evaluate efficacy of Shingigu and Charcoal moxibustion scientifically and objectively.

Detailed description: Moxibustion is traditional treatment that regulate circulation of Qi-blood by making the body warm to prevent and treat disease. Recently many kinds of moxibustion and moxibustion apparatus were developed. However evaluating efficacy of moxibustion is insufficient. Thus, there is need for objective evaluating about efficacy of moxibustion.

Eligibility criteria: Inclusion Criteria:

* 18\~65 years old

Exclusion Criteria:

* Hyperthyroidism
* Heart disease(Heart failure, angina pectoris, myocardial infarction)
* Uncontrolled hypertension (SBP\>145mmHg or DBP\>95mmHg)
* Severe renal disorder
* Severe liver disorder
* Diabetes Mellitus
* Female are in the duration of pregnancy

Primary outcomes:
measure: Temperature Change after moxa treatment
timeFrame: 30 minutes after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Chungju
country: Korea, Republic of
facility: Semyung University Chungju Hospital
state: Chungbuk
Study officials:
affiliation: Semyung University Chungju Hospital
name: Hoyeon Go, O.M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06254456: Fluid Responsiveness in Prone Patients
Official title: End Expiratory Occlusion Test and Tidal Volume Challenge Test for Assess Fluid Responsiveness in Prone Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Fluid Responsiveness
Keywords: Fluid responsiveness, prone, EEOT, TVC, ARDS
Lead sponsor: Bhumibol Adulyadej Hospital
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: To assess fluid responsiveness in prone patient


Eligibility criteria: Inclusion Criteria:

* patients planed to prone position for treatment

Exclusion Criteria:

* no consent
* arrhythmia
* pregnancy
* pre existing pneumothorax
* pre existing fluid overload
* cannot insert arterial or central venous catheters

Primary outcomes:
measure: Pulse Pressure Variation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00427856: Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Official title: A Multi-Center, Open-Label, Phase II Study of Sequential, Single-Agent Obatoclax Mesylate (GX15-070MS)Followed by a Combination With Rituximab to Patients With Previously-Untreated Follicular Lymphoma (FL)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lymphoma, Follicular
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2007-01-29
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

Detailed description: This is a multi-center, open-label, Phase II study of obatoclax administered alone as a weekly, 3-hour or 24-hour infusion for 12 weeks followed by a combination with rituximab to patients with previously-untreated Follicular Lymphoma. For purposes of clinical evaluations, treatment cycles will occur in 4-week periods. Treatment may be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.

Eligibility criteria: Inclusion Criteria:

* Pathological confirmation of Follicular Lymphoma (FL)
* Must have advanced stage disease
* Must not have received any prior chemotherapy or immunotherapy for lymphoma, including steroids
* Must have adequate organ function
* Must have the ability to understand and willingness to sign a written informed consent form

Exclusion Criteria:

* No other agents or therapies administered with the intent to treat malignancy
* Uncontrolled, intercurrent illness
* Pregnant women and women who are breast feeding

Primary outcomes:
measure: Response rate
timeFrame: 12 weeks
Secondary outcomes:
measure: Time to Tumor Progression.
timeFrame: 20 weeks
Other outcomes:
Locations:
city: Hackensack
country: United States
facility: The Cancer Center at Hackensack University Medical Center
state: New Jersey
Study officials:
affiliation: Gemin X, Inc.
name: Jean Viallet, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00959556: Study of Blood Samples in Patients With Breast Cancer
Official title: Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: recurrent breast cancer
stage IA breast cancer
stage IB breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2009-08-14
Enrollment: 900
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.

PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.

Detailed description: OBJECTIVES:

* Identify constitutional gene variants associated with a change in response.

OUTLINE: Blood samples are collected periodically for analysis of genetic factors.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed breast carcinoma
* Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
* Patient agrees to conservative surgery
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Menopausal status not specified
* No contraindication for chemotherapy comprising anthracyclines and/or taxanes

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior adjuvant therapy

Primary outcomes:
measure: Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)
Secondary outcomes:
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
Study officials:
affiliation: Centre Oscar Lambret
name: Jacques Bonneterre, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01445756: Topical Lidocaine for Pain Control With Intrauterine Device (IUD) Insertion
Official title: Topical Lidocaine for Pain Control With IUD Insertion: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Pain
Keywords: Intrauterine Device
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2011-10-04
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Intrauterine contraception is a very effective, long term, reversible form of birth control, and is increasingly used in young, nulliparous patients. However, there is potential for pain with insertion of an Intrauterine Device (IUD) - particularly in patients without a previous history of vaginal delivery. The potential pain associated with insertion is often a significant barrier for patients when choosing and IUD for contraception. Several methods of pain control have been studied, but none have been shown to reduce pain at time of insertion. Our research question is to determine if 2% topical lidocaine gel, instilled into the cervical canal, will reduce maximum pain at time of insertion of a popular IUD (Mirena Intrauterine System) in young, nulliparous patients. This will be studied in a randomized, double-blind placebo-controlled trial.

Detailed description: The investigators research question is to determine if 2% topical lidocaine gel, instilled into the cervical canal, will reduce maximum pain at time of insertion of a popular IUD (Mirena Intrauterine System) in young, nulliparous patients. This will be studied in a randomized, double-blind placebo-controlled trial.

Eligibility criteria: Inclusion Criteria:

* Must be at least 18 years old

Exclusion Criteria:

* Age \<18
* Non-English speaking
* Illiterate
* History of pregnancy with delivery \>20 weeks
* History of prior IUD insertion or attempt

Primary outcomes:
measure: Change in pain level from no Lidocaine administered to after Lidocaine is administered
timeFrame: Pain assessments prior to procedure, immediately after procedure, and 10 minutes after the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: University Health Services Women's Care Clinic
state: Wisconsin
Study officials:
affiliation: University of Wisconsin Health Services
name: Mary Landry, MD
role: PRINCIPAL_INVESTIGATOR
References: